Foamix Pharmaceuticals (FOMX) PT Doubled to $20 at Guggenheim

August 10, 2016 10:53 AM EDT
Get Alerts FOMX Hot Sheet
Price: $9.33 +0.86%

Rating Summary:
    4 Buy, 0 Hold, 0 Sell

Rating Trend: = Flat

Today's Overall Ratings:
    Up: 14 | Down: 19 | New: 11
Trade FOMX Now!
Join SI Premium – FREE

Get daily under-the-radar research with's Stealth Growth Insider Get your 2-Wk Free Trial here.

Guggenheim analyst Louise Chen reiterated a Buy rating and doubled her price target on Foamix Pharmaceuticals (NASDAQ: FOMX) to $20.00 (from $10.00).

Chen commented, "The increase in our PT is driven by multiple expansion, as FOMX continues to make good progress on advancing its pipeline. We arrive at our new PT by using a DCF analysis. We still expect upward earnings revisions to drive shares higher, led by: 1) Peak sales of FMX101 reaching $500MM+, which would translate into $7.36 in EPS; 2) Sales from FOMX's other assets (FMX103, FMX102, FDX104); 3) Applying FOMX's technology outside of dermatology; and 4) Potential acquisition of commercial infrastructure to launch FMX101.

The analyst noted the following positives from the call and release that support their thesis:

1) Commenced Phase 3 trial for FMX101 in patients with moderate to severe acne. Patient enrollment is progressing as planned with topline results expected in 1H17;

2) Completed enrollment in Phase 2 FMX103 trial for rosacea, topline results expected before year end '16;

3) Plan to conduct a phototoxicity study later this year for FMX102, with results expected in '16;

4) Continue to develop FDX104 for acne-like rash in cancer patients;

5) Sales of Finacea Foam in the U.S. was up 10% sequentially from 1Q16; and,

6) Cash and equivalents of $90.9MM as of 6/30/16.

For an analyst ratings summary and ratings history on Foamix Pharmaceuticals click here. For more ratings news on Foamix Pharmaceuticals click here.

Shares of Foamix Pharmaceuticals closed at $8.14 yesterday.

Serious News for Serious Traders! Try Premium Free!

You May Also Be Interested In

Related Categories

Analyst Comments, Analyst EPS View, Analyst PT Change

Related Entities

Earnings, Definitive Agreement, Louise Chen, Guggenheim

Add Your Comment